Ovarian function after autologous bone marrow transplantation.

PubWeight™: 0.94‹?› | Rank: Top 15%

🔗 View Article (PMID 9667251)

Published in J Clin Oncol on July 01, 1998

Authors

A D Schimmer1, M Quatermain, K Imrie, V Ali, J McCrae, A K Stewart, M Crump, C Derzko, A Keating

Author Affiliations

1: University of Toronto Autologous Blood and Marrow Transplant Program and the Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.

Articles by these authors

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55

Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy (2005) 5.92

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91

Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91

Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69

Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells. Mol Cell Biol (1986) 2.51

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50

Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg (2000) 2.48

Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant (2007) 2.47

Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys (2001) 2.33

Isolated chloroma: the effect of early antileukemic therapy. Ann Intern Med (1995) 2.29

Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer (2000) 2.11

Superior survival of young women with malignant melanoma. Am J Surg (1998) 2.09

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77

High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood (1998) 1.72

Structure and content of the Entamoeba histolytica genome. Adv Parasitol (2007) 1.62

Gastric carcinoma: does lymph node dissection alter survival? J Am Coll Surg (1996) 1.62

The National Cancer Data Base report on carcinoma of the gallbladder, 1989-1995. Cancer (1998) 1.59

Combined spinal and epidural anesthesia for cesarean section in a parturient with moyamoya disease. Acta Anaesthesiol Scand (1998) 1.51

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol (2006) 1.51

Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose. J Clin Oncol (1996) 1.47

Immunoglobulin heavy chain gene expression in peripheral blood B lymphocytes. J Clin Invest (1992) 1.46

Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Eur J Cancer (1999) 1.44

Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res (1993) 1.44

High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med (2000) 1.42

Biology of bone marrow stroma. Ann N Y Acad Sci (1995) 1.41

Acute transient parotitis after high dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant (1990) 1.40

An evaluation of outpatient bone marrow harvesting. J Clin Oncol (1989) 1.39

Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol (2000) 1.36

Donor origin of the in vitro haematopoietic microenvironment after marrow transplantation in man. Nature (1982) 1.35

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol (2001) 1.34

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol (2003) 1.32

Transplanted adult spinal cord-derived neural stem/progenitor cells promote early functional recovery after rat spinal cord injury. Neuroscience (2008) 1.28

A STUDY OF EIGHT HUNDRED AND FIFTY CASES OF SCARLET FEVER WITH A MORE PARTICULAR CONSIDERATION OF SEVENTY-ONE FATAL CASES: Part I. Can Med Assoc J (1911) 1.25

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia (2008) 1.24

Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood (1996) 1.24

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol (2011) 1.23

The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996. Cancer (2000) 1.23

Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field-mediated DNA transfer. Proc Natl Acad Sci U S A (1986) 1.23

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood (2000) 1.21

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia (2013) 1.21

Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood (2000) 1.21

Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.21

Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. J Clin Oncol (1995) 1.20

Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood (1999) 1.20

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 1.17

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol (2006) 1.17

The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer (1996) 1.13

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol (2013) 1.11

HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells. Oncogene (2001) 1.11

Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol (2001) 1.11

Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma. Ann Oncol (2007) 1.08

The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-95. Cancer (1998) 1.06

Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood (1999) 1.06

Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on longterm survival. J Am Coll Surg (1997) 1.05

Intrathecal transplantation of stem cells by lumbar puncture for thoracic spinal cord injury in the rat. Spinal Cord (2011) 1.04

Electric field-mediated gene transfer: characterization of DNA transfer and patterns of integration in lymphoid cells. Nucleic Acids Res (1988) 1.04

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol (2001) 1.04

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol (2004) 1.04

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol (2003) 1.04

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol (1993) 1.03

Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol (1999) 1.03

Peptide mimics as substrates for the intestinal peptide transporter. J Biol Chem (1998) 1.02

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol (1999) 1.02

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant (2005) 1.01

Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood (2000) 1.01

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol (2010) 1.01

Simian virus 40-transformed adherent cells from human long-term marrow cultures: cloned cell lines produce cells with stromal and hematopoietic characteristics. Blood (1987) 1.01

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant (2004) 0.99

Characterization of pica prevalence among patients with sickle cell disease. Arch Pediatr Adolesc Med (2001) 0.99

Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer (2000) 0.99

Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Res Clin Pract (2001) 0.99

The CD34 antigen: structure, biology, and potential clinical applications. J Hematother (1992) 0.98

Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol (1994) 0.98

E2F1 and p53 are dispensable, whereas p21(Waf1/Cip1) cooperates with Rb to restrict endoreduplication and apoptosis during skeletal myogenesis. Dev Biol (2000) 0.97

Benign intracranial hypertension and anesthesia for cesarean section. Anesthesiology (1985) 0.97

Prevalence of antibody to Chlamydia trachomatis in spontaneous abortion and infertility. Am J Obstet Gynecol (1987) 0.97

The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer (1999) 0.97

Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant (2001) 0.96

CGA-7 and HHF, two monoclonal antibodies that recognize muscle actin and react with adherent cells in human long-term bone marrow cultures. Blood (1985) 0.96

The generation of human long-term marrow cultures from marrow depleted of Ia (HLA-DR) positive cells. Blood (1984) 0.96

Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age. Bone Marrow Transplant (2003) 0.95

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol (2011) 0.95

Testicular plasmacytoma following chemical orchiectomy: potential role of hypogonadism in myeloma proliferation. Leuk Lymphoma (1998) 0.95

The National Cancer Data Base: report on kidney cancers. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer (1997) 0.95

Disease severity and radioactive iodine use for thyroid cancer. J Clin Endocrinol Metab (2013) 0.94

Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant (2000) 0.94

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant (2008) 0.94

Malakoplakia: evidence for an acquired disease secondary to immunosuppression. Transplantation (1981) 0.94

Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J (2013) 0.94

Hematopoietic stem cells engraft in untreated transplant recipients. Exp Hematol (1993) 0.94